Top

Published in:

01-10-2020 | Insulins

Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis

Authors: Mattia Barbot, Daniela Regazzo, Alessandro Mondin, Marialuisa Zilio, Laura Lizzul, Martina Zaninotto, Mario Plebani, Giorgio Arnaldi, Filippo Ceccato, Carla Scaroni

Published in: Pituitary | Issue 5/2020

Abstract

Introduction

Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM). The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset.

Methods

Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34–50]) were submitted to an acute PAS test (600 µg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 µg, and followed up with clinical and hormone assessments for a median of 6 months [2–13].

Results

PAS prompted a significant decrease in all hormonal parameters considered except for glycemia, which increased (as expected), reaching the highest value at 120′ (p < 0.0001). Overall, 9/15 patients developed DM within 2 months of starting PAS therapy. There were no differences in age, weight, visceral adiposity, HOMA index, fasting glucose or severity of CD between patients who developed DM and those who did not. Baseline fasting glucagon levels were higher in the DM patients (17.95 [12.45–20.54] vs. 10.53 [8.11–12.33] pmol/L, p = 0.0256), and so were GIP and HbA1c levels (37 [5.5–39.5] vs. 29 [27–31.8] mmol/mol, p = 0.0008). Glucose at 120′ was also significantly higher in the DM patients (9.5 [8.65–11.95] vs. 6.85 [4.48–9] mmol/L, p = 0.012).

Conclusions

PAS was rapidly able to suppress insulin and incretin secretion, with a subsequent rise in glucose levels into the diabetic range. It also induced a significant inhibition of glucagon production. The patients at higher risk of DM during PAS therapy were those with higher glucagon levels, HbA1c > 34.5 mmol/mol, and a glucose peak after PAS administration > 9 mmol/L. CD patients with these features given PAS therapy should therefore be monitored more carefully.

Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100(8):2807–2831. https://doi.org/10.1210/jc.2015-1818CrossRefPubMedPubMedCentral

Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A (2019) Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol 7(4):300–312. https://doi.org/10.1016/S2213-8587(18)30155-4CrossRefPubMed

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716CrossRef

Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A (2016) Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. J Endocrinol Invest 39(2):235–255. https://doi.org/10.1007/s40618-015-0404-6CrossRefPubMed

Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48(1):77–85CrossRef

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924. https://doi.org/10.1056/NEJMoa1105743 (Erratum in: N Engl J Med. 2012 Aug 23;367(8):780)CrossRefPubMed

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453. https://doi.org/10.1210/jc.2013-1771CrossRefPubMed

Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103(3):458–465. https://doi.org/10.1016/j.diabres.2013.12.011CrossRefPubMed

Barbot M, Ceccato F, Scaroni C (2018) Diabetes mellitus secondary to Cushing’s disease. Front Endocrinol (Lausanne) 9:284. https://doi.org/10.3389/fendo.2018.00284 ( eCollection 2018)CrossRef

10.

Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186. https://doi.org/10.1007/s11102-013-0483-3CrossRefPubMed

11.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28(7):412–419CrossRef

12.

Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J (1995) A simple measure of insulin resistance. Lancet. 346(8967):120–121CrossRef

13.

Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4):920–922. https://doi.org/10.2337/dc09-1825CrossRefPubMedPubMedCentral

14.

American Diabetes Association (2020) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 43(Suppl1):S14–S31. https://doi.org/10.2337/dc20-S002CrossRef

15.

Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH (2003) Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28(7):916–931CrossRef

16.

Barbot M, Guarnotta V, Zilio M, Ceccato F, Ciresi A, Daniele A, Pizzolanti G, Campello E, Frigo AC, Giordano C, Scaroni C (2018) Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease. Endocrine 62(1):207–214. https://doi.org/10.1007/s12020-018-1669-2CrossRefPubMed

17.

Pivonello R, Arnaldi G, Scaroni C, Giordano C, Cannavò S, Iacuaniello D, Trementino L, Zilio M, Guarnotta V, Albani A, Cozzolino A, Michetti G, Boscaro M, Colao A (2019) The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence". Endocrine 64(3):657–672. https://doi.org/10.1007/s12020-018-1818-7CrossRefPubMedPubMedCentral

18.

Trementino L, Michetti G, Angeletti A, Marcelli G, Concettoni C, Cardinaletti C, Polenta B, Boscaro M, Arnaldi G (2016) A Single-center 10-year experience with pasireotide in Cushing’s disease: patients’ characteristics and outcome. Horm Metab Res 48(5):290–298. https://doi.org/10.1055/s-0042-101347CrossRefPubMed

19.

Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK (2017) Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57(1):156–165. https://doi.org/10.1007/s12020-017-1316-3CrossRefPubMedPubMedCentral

20.

Trementino L, Zilio M, Marcelli G, Michetti G, Barbot M, Ceccato F, Boscaro M, Scaroni C, Arnaldi G (2015) The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing’s disease: findings from a pilot study. Endocrine 50(1):154–161. https://doi.org/10.1007/s12020-014-0499-0CrossRefPubMed

21.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, 2305 Study Group, Pasireotide B (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81(3):408–417. https://doi.org/10.1111/cen.12431CrossRef

22.

Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57(3):678–687CrossRef

23.

Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86(8):3717–3723CrossRef

24.

Shekhawat VS, Bhansali S, Dutta P, Mukherjee KK, Vaiphei K, Kochhar R, Sinha SK, Sachdeva N, Kurpad AV, Bhat K, Mudaliar S, Bhansali A (2019) Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly. Sci Rep. 9(1):5646. https://doi.org/10.1038/s41598-019-41887-7CrossRefPubMedPubMedCentral

25.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301–307CrossRef

26.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S (2008) Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 51(4):632–640. https://doi.org/10.1007/s00125-008-0943-xCrossRefPubMed

27.

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837. https://doi.org/10.1016/j.cmet.2013.04.008CrossRefPubMed

28.

Campbell JE, Drucker DJ (2015) Islet α cells and glucagon–critical regulators of energy homeostasis. Nat Rev Endocrinol 11(6):329–338. https://doi.org/10.1038/nrendo.2015.51CrossRefPubMed

29.

Hædersdal S, Lund A, Knop FK, Vilsbøll T (2018) The role of glucagon in the pathophysiology and treatment of Type 2 diabetes. Mayo Clin Proc 93(2):217–239. https://doi.org/10.1016/j.mayocp.2017.12.003CrossRefPubMed

30.

Guarnotta V, Amato MC, Pivonello R, Arnaldi G, Ciresi A, Trementino L, Citarrella R, Iacuaniello D, Michetti G, Simeoli C, Colao A, Giordano C (2017) The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome. Endocrine 55(2):564–572. https://doi.org/10.1007/s12020-016-0914-9CrossRefPubMed

31.

Trementino L, Appolloni G, Concettoni C, Cardinaletti M, Boscaro M, Arnaldi G (2012) Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur J Endocrinol 166(1):35–42. https://doi.org/10.1530/EJE-11-0722CrossRefPubMed

32.

Barbot M, Ceccato F, Scaroni C (2019) The pathophysiology and treatment of hypertension in patients with Cushing’s syndrome. Front Endocrinol (Lausanne) 10:321. https://doi.org/10.3389/fendo.2019.00321CrossRef

33.

Iwen KA, Senyaman O, Schwartz A, Drenckhan M, Meier B, Hadaschik D, Klein J (2008) Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. J Endocrinol. 196(3):465–472. https://doi.org/10.1677/JOE-07-0299CrossRefPubMed

34.

Scaroni C, Zilio M, Foti M, Boscaro M (2017) Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. Endocr Rev 38(3):189–219. https://doi.org/10.1210/er.2016-1105CrossRefPubMed

35.

American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74. https://doi.org/10.2337/dc13-S067CrossRef

36.

Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, Imperatore G, Williams DE, Albright AL (2010) A1C level and future risk of diabetes: a systematic review. Diabetes Care 33(7):1665–1673. https://doi.org/10.2337/dc09-1939CrossRefPubMedPubMedCentral

37.

Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2015) Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18(3):359–365. https://doi.org/10.1007/s11102-014-0582-9CrossRefPubMed

38.

Toft-Nielson M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45(5):552–556CrossRef

39.

Ahrén B, Carr RD, Deacon CF (2010) Incretin hormone secretion over the day. Vitam Horm 84:203–220. https://doi.org/10.1016/B978-0-12-381517-0.00007-2CrossRefPubMed

Title: Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis
Authors: Mattia Barbot
Daniela Regazzo
Alessandro Mondin
Marialuisa Zilio
Laura Lizzul
Martina Zaninotto
Mario Plebani
Giorgio Arnaldi
Filippo Ceccato
Carla Scaroni
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Insulins
Diabetes
Insulins
Published in: Pituitary / Issue 5/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-020-01055-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

The diagnosis and management of primary and iatrogenic soft tissue sarcomas of the sella

Cosecreting TSH/GH pituitary adenomas—an 8-year experience in a single tertiary center

Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients‘ perspective

Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature

High accuracy of bilateral and simultaneous petrosal sinus sampling with desmopressin for the differential diagnosis of pediatric ACTH-dependent Cushing’s syndrome

Feasibility of machine learning based predictive modelling of postoperative hyponatremia after pituitary surgery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials